Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) dropped 2.1% on Monday . The stock traded as low as $1.84 and last traded at $1.90. Approximately 122,319 shares were traded  during mid-day trading, an increase of 169% from the average daily volume of 45,420 shares. The stock had previously closed at $1.94.

Cyclo Therapeutics Stock Performance

The firm has a 50-day simple moving average of $1.65 and a two-hundred day simple moving average of $1.96. The company has a market capitalization of $16.12 million, a price-to-earnings ratio of -1.20 and a beta of -0.53.

Get Cyclo Therapeutics alerts:

Hedge Funds Weigh In On Cyclo Therapeutics

An institutional investor recently raised its position in Cyclo Therapeutics stock. Renaissance Technologies LLC grew its stake in  Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) by 14.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 75,787 shares of the company's stock after buying an additional 9,487 shares during the quarter. Renaissance Technologies LLC owned 1.17% of Cyclo Therapeutics worth $240,000 as of its most recent filing with the SEC. Institutional investors own  4.77% of the company's stock.

Cyclo Therapeutics Company Profile

(Get Rating)

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease.